First-in-human study of CDNF in patients with Parkinson's disease
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs CDNF (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Herantis Pharma
- 27 Sep 2017 According to a Herantis Pharma media release, first study site, Karolinska University Hospital in Stockholm, Sweden, has already consented the first patient in the study. Two further study sites, Helsinki University Hospital in Finland and Lund University Hospital in Sweden, are planned to initiate patient recruitment as soon as the required safety data cumulate from the first study site.
- 27 Sep 2017 Status changed from planning to recruiting, according to a Herantis Pharma media release.
- 29 Aug 2017 According to a Herantis Pharma media release, begning of patient recuitment is expected at in Q3/2017.